EUROPAC2 Trial to investigate the efficacy of ANTOX 1.2 and MGCT (Magnesiocard ) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis.
Dear Mr Armour,
I am the trial coordinator for the EUROPAC2 trial; a double blind randomised controlled trial to investigate the efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard ) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis.
As Dr Greenhalf informs me that you have supported the trial in the past I am writing to give you an update of our current position and to request your continued support.
The trial, which is being run through the Liverpool Cancer Trials Unit, opened in the UK earlier this year and is currently recruiting patients from the Northwest region to the Royal Liverpool site. We are working with other hospital trusts towards opening additional recruitment centres and hope we will have a minimum of three more sites by the end of 2007.
More details regarding the trial and a leaflet to be downloaded can be found on the LCTU webpage: http://www.lctu.org.uk/trial/europac-2.html
I would be very grateful if you could share this information and/or my contact details shown below with any members of your network which may find the information useful.
Liverpool Cancer Trials Unit
University of Liverpool Cancer Research Centre
200 London Road
Mob: 07807 106 511
Tel: 0151 7948933
Fax: 0151 7948930